NASDAQ$HSIC
Henry Schein Inc · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Reported mixed results with sales increase slightly but EPS decreased significantly due to restructuring and integration costs.
Henry Schein reported a slight increase in fourth-quarter net sales, but GAAP diluted EPS decreased significantly. The company introduced 2023 financial guidance, expecting operating income growth when excluding the contribution from PPE products and COVID-19 test kits.
- Fourth-quarter net sales increased 1.2% to $3.4 billion compared to the fourth quarter of 2021.
- Fourth-quarter GAAP diluted EPS was $0.34, compared to $1.05 in the fourth quarter of 2021.
- Fourth-quarter non-GAAP diluted EPS was $1.21, compared to $1.07 in the fourth quarter of 2021.
- Introduced guidance for 2023 non-GAAP diluted EPS of $5.25 to $5.42, excluding amortization expense of acquired intangible assets.
Headline financials
Revenue & EPS history
Henry Schein · Revenue · Quarterly
$3.37B
Revenue by segment
Henry Schein · $3.18B total across 2 segments · Q4 2022
- Global Dental$2.01B-0.6%63.0%
- Global Medical$1.18B+3.8%37.0%
Forward guidance
Henry Schein introduced guidance for 2023 non-GAAP diluted EPS to be $5.25 to $5.42.
Tailwinds
- Guidance reflects high single-digit to low double-digit growth in non-GAAP operating income over 2022 when excluding the contribution from PPE products and COVID-19 test kits.
- 2023 sales growth is expected to be approximately 1% to 3% over 2022.
- Fundamentals in the dental end market remain solid.
- Demand for dental equipment in North America remains healthy, and the North America equipment order book is stable.
- Growth in the Technology and Value -added Services business was strongest in the international business due to the strength of our Dentally cloud-based solution.
Headwinds
- 2023 non-GAAP diluted EPS excludes amortization expense of prior acquisitions of $0.56 in 2023 and $0.57 in 2022.
- 2023 sales of PPE products and COVID-19 test kits are expected to decrease in aggregate by approximately 30% to 35% from 2022.
- 2023 non-GAAP operating margin is expected to be 10 to 15 basis points below 2022 non-GAAP operating margin of 8.20%, largely a result of lower PPE products and COVID-19 test kit sales and profits.
- The impact on 2023 non-GAAP diluted EPS from lower contributions to earnings from sales of PPE products and COVID-19 test kits is expected to be approximately $0.35 to $0.40.
- Global dental consumable merchandise growth was impacted by a high incidence of flu and COVID-19 cases, which caused increased rates of patient appointment cancellations and furthered staffing shortages.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2022
-0.4%
Avg return
Earnings day
-0.5%
Avg return
5 days after
-0.6%
Avg return
30 days after
45%
31 / 69 earnings
Positive
+11.1%
Q4 2021
Best reaction
-8.5%
Q3 2017
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.3% | -1.6% | +4.6% | |
| Q4 2025 | +5.8% | +2.3% | -8.5% | |
| Q3 2025 | +10.9% | +11.2% | +13.5% | |
| Q1 2025 | +2.0% | +5.1% | +7.8% | |
| Q4 2024 | -2.3% | -7.0% | -10.6% | |
| Q3 2024 | -3.2% | -6.0% | +0.2% | |
| Q2 2024 | -5.4% | -0.9% | +0.4% | |
| Q1 2024 | +6.2% | +7.0% | +0.1% | |
| Q4 2023 | -5.1% | -4.6% | -6.3% | |
| Q3 2023 | +7.5% | +7.3% | +15.5% | |
| Q2 2023 | -2.8% | -1.8% | -5.1% | |
| Q1 2023 | -4.5% | -4.2% | -6.1% | |
| Q4 2022 | -6.2% | -7.5% | -12.8% | |
| Q3 2022 | +1.8% | +6.2% | +21.2% | |
| Q2 2022 | -4.9% | -3.8% | -7.3% | |
| Q1 2022 | +7.4% | +6.6% | +5.6% | |
| Q4 2021 | +11.1% | +10.1% | +14.5% | |
| Q3 2021 | +3.0% | +4.5% | -6.7% | |
| Q2 2021 | -4.8% | -5.2% | -2.3% | |
| Q1 2021 | +6.6% | +8.9% | +5.3% | |
| Q4 2020 | -8.5% | -6.5% | -5.3% | |
| Q3 2020 | -5.0% | -3.0% | +4.6% | |
| Q2 2020 | -5.3% | -4.4% | -6.9% | |
| Q1 2020 | +0.4% | +2.9% | +20.6% | |
| Q4 2019 | -8.4% | -14.4% | -38.9% | |
| Q3 2019 | +4.4% | +4.8% | +5.2% | |
| Q2 2019 | -3.2% | -2.3% | -4.2% | |
| Q1 2019 | +8.6% | +8.9% | +8.6% | |
| Q4 2018 | -5.0% | -5.2% | -5.2% | |
| Q3 2018 | +3.1% | +0.8% | +3.3% | |
| Q2 2018 | -0.5% | -3.6% | +0.5% | |
| Q1 2018 | -6.1% | -4.4% | -6.7% | |
| Q4 2017 | -1.2% | -2.1% | -5.2% | |
| Q3 2017 | -8.5% | -13.6% | -13.0% | |
| Q2 2017 | -7.7% | -7.2% | -4.9% | |
| Q1 2017 | +0.6% | +0.3% | +5.2% | |
| Q4 2016 | +2.7% | +3.2% | +2.0% | |
| Q3 2016 | +4.6% | +6.2% | +1.7% | |
| Q2 2016 | -7.1% | -8.4% | -8.6% | |
| Q1 2016 | -2.5% | — | — | |
| Q4 2015 | +7.0% | — | — | |
| Q3 2015 | +1.1% | — | — | |
| Q2 2015 | -1.9% | — | — | |
| Q1 2015 | -0.4% | — | — | |
| Q4 2014 | +0.9% | — | — | |
| Q3 2014 | +5.4% | — | — | |
| Q2 2014 | -1.8% | — | — | |
| Q1 2014 | -1.7% | — | — | |
| Q4 2013 | +0.1% | — | — | |
| Q3 2013 | -2.6% | — | — | |
| Q2 2013 | -0.3% | — | — | |
| Q1 2013 | +2.1% | — | — | |
| Q4 2012 | -2.2% | — | — | |
| Q3 2012 | -0.6% | — | — | |
| Q2 2012 | +1.8% | — | — | |
| Q1 2012 | +2.4% | — | — | |
| Q4 2011 | +3.4% | — | — | |
| Q3 2011 | -6.4% | — | — | |
| Q2 2011 | -2.3% | — | — | |
| Q1 2010 | -2.0% | — | — | |
| Q1 2011 | +0.5% | — | — | |
| Q4 2010 | -3.9% | — | — | |
| Q1 2009 | -3.9% | — | — | |
| Q4 2008 | -3.9% | — | — | |
| Q3 2009 | -4.1% | — | — | |
| Q3 2010 | -4.1% | — | — | |
| Q2 2010 | +2.1% | — | — | |
| Q4 2009 | +2.1% | — | — | |
| Q2 2009 | +2.1% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro